Comparison of the efficacy and adherence of generic and brand-name entecavirs in chronic hepatitis B patients: a multicenter cohort study

doi:10.5246/jcps.2021.12.085

Abstract

Abstract:

In the present study, we aimed to compare the efficacy and adherence of Runzhong^? (generic drug, Chiatai Tianqing, Nanjing) and Baraclude^? (branded drug, Bristol-Myers Squibb) in patients with chronic hepatitis B. We collected patient data from three hospitals within 48 weeks and compared the two groups by using the propensity-score matching method. A total of 4889 patients were enrolled in this study; 503 initiated a brand-name drug, and 4386 received a generic drug. There was no significant difference in the rates of CVR (complete virologic response) and VB (virologic breakthrough) between the Runzhong^? group and Baraclude^? group at 24 and 48 weeks. Similar results for HBeAg loss, medication possession ratio (MPR), and biological response were obtained. Age, gender (HR 0.909 (0.842–0.981)), normal baseline ALT rate (HR 0.789 (0.731–0.851)), HBeAg-positive rate, and baseline undetectable HBV DNA rate (HR 0.306 (0.234–0.399)) were independent factors for achieving CVR.

Key words: Entecavir, Adherence, Generic drug, Branded drug

Supporting:

Ying Xie, Hanqiu Zhan, Xiaohong Zhu, Yuan Li, Ruyi Tian, Jing Zhang, Shanshan Chen, Yanling Zhao. Comparison of the efficacy and adherence of generic and brand-name entecavirs in chronic hepatitis B patients: a multicenter cohort study[J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(12): 986-993.

Figures/Tables 4

References 23

[1]	Schweitzer, A.; Horn, J.; Mikolajczyk, R.T.; Krause, G.; Ott, J.J. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015, 386, 1546–1555.
[2]	Chen, C.J. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006, 295, 65–73.
[3]	Iloeje, U.H.; Yang, H.I.; Su, J.; Jen, C.L.; You, S.L.; Chen, C.J.;. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006, 130, 678–686.
[4]	WHO. Fact sheet hepatitis B. 2021. This article can be found online at https://www.who.int/news-room/fact-sheets/detail/hepatitis-b.
[5]	Shan, S.; Jia, J.D. Advances and challenge in prevention and treatment of hepatitis B in China. Chin. J. Viral Dis. 2017, 7, 5–8.
[6]	Chien, R.N.; Kao, J.H.; Peng, C.Y.; Chen, C.H.; Liu, C.J.; Huang, Y.H.; Hu, T.H.; Yang, H.I.; Lu, S.N.; Ni, Y.H.; Chuang, W.L.; Lee, C.M.; Wu, J.C.; Chen, P.J.; Liaw, Y.F. Taiwan consensus statement on the management of chronic hepatitis B. J. Formos. Med. Assoc. 2019, 118, 7–38.
[7]	Ruggeri, M.; Basile, M.; Coretti, S.; Drago, C.; Cicchetti, A. Economic analysis and budget impact of tenofovir and entecavir in the first-line treatment of hepatitis B virus in Italy. Appl. Heal. Econ. Heal. Policy. 2017, 15, 479–490.
[8]	Diseases, C.S.o.I.; Association, C.M.; Hepatology, C.S.o.; Association, C.M. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019). J. Clin. Hepatol. 2019, 35, 1–22.
[9]	Terrault, N.A.; Lok, A.S.F.; McMahon, B.J.; Chang, K.M.; Hwang, J.P.; Jonas, M.M.; Brown, R.S. Jr, Bzowej, N.H.; Wong, J.B. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018, 67, 1560–1599.
[10]	Liu, J.; Liang, W.; Jing, W.; Liu, M. Countdown to 2030: eliminating hepatitis B disease, China. Bull. World Heal. Organ. 2019, 97, 230–238.
[11]	Tang, M.; He, J.; Chen, M.; Cong, L.; Xu, Y.; Yang, Y.; Hou, Z.; Song, P.; Jin, C. "4+7" city drug volume-based purchasing and using pilot program in China and its impact. Drug Discov. Ther. 2019, 13, 365–369.
[12]	McMahon, J.H.; Jordan, M.R.; Kelley, K.; Bertagnolio, S.; Hong, S.Y.; Wanke, C.A.; Lewin, S.R.; Elliott, J.H. Pharmacy adherence measures to assess adherence to antiretroviral therapy: review of the literature and implications for treatment monitoring. Clin. Infect. Dis. 2011, 52, 493–506.
[13]	Xu, J.H.; Yu, Y.Y.; Si, C.W.; Zeng, Z.; Li, J.; Mao, Q.; Zhang, D.Z.; Tang, H.; Sheng, J.F.; Chen, X.Y. Analysis of a randomized, double-blind, double-dummy, controlled, multicenter study confirmed the similar therapeutic eflicacies of entecavir maleate and entecavir for treatment of HBeAg-positive chronic hepatitis B. Chin. J. Hepatol. 2014, 32, 594–600.
[14]	Kim, D.Y.; Kim, J.H.; Tak, W.Y.; Yeon, J.E.; Lee, J.H.; Yoon, J.H.; Lee, Y.J.; Lee, B.S.; Han, B.H.; Lee, H.C. Baracle^® vs Baraclude^® for 48 weeks in patients with treatment-naïve chronic hepatitis B: a comparison of efficacy and safety. Drug Des. Devel. Ther. 2017, 11, 3145–3152.
[15]	Jia, J.; Tang, H.; Ning, Q.; Jiang, J.; Dou, X.; Zhang, M.; Zhang, S.; Shang, J.; Lu, W.; Ye, Y.; Wang, X.; Li, M.; Liu, J.; Bo, Q.; Tan, W.; EVOLVE Study Group. Real-world evidence for nucleoside/nucleotide analogues in a 5-year multicentre study of antiviral-naive chronic hepatitis B patients in China: 52-week results. Antivir. Ther. 2018, 23, 201–209.
[16]	Hou, J.L.; Cheng, M.L.; Zhao, W.; Tang, H.; Zhang, L.X.; Xu, D.Z.; Tian, D.Y.; Xie, Q.; Lin, S.M.; Gao, Z.L. A 5-year controlled study comparing the efficacy and safety of entecavir and other nucleoside (acid) drugs in newly treated patients with chronic hepatitis B in clinical practice in China. Paper Collection of the 13th National Conference on Infectious Diseases of the Chinese Medical Association. 2014.
[17]	Committee, E.C.A.E. Expert consensus on clinical application of entecavir: an update in 2015. J. Clin. Hepatol. 2016, 19–25.
[18]	Ono, A.; Suzuki, F.; Kawamura, Y.; Sezaki, H.; Hosaka, T.; Akuta, N.; Kobayashi, M.; Suzuki, Y.; Saitou, S.; Arase, Y.; Ikeda, K.; Kobayashi, M.; Watahiki, S.; Mineta, R.; Kumada, H. Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients. J. Hepatol. 2012, 57, 508–514.
[19]	Zheng, M.H.; Shi, K.Q.; Dai, Z.J.; Ye, C.; Chen, Y.P. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients. Clin. Ther. 2010, 32, 649–658.
[20]	Lin, Q.; Zhang, D.Z.; Zhou, Z.; Hu, P.; Ren, H. Comparison of the efficacy of 48 week-Entecavir therapy with that of Adefovir therapy for chronic hepatitis B patients. Chin. J. Hepatol. 2010, 18, 338–41.
[21]	Zuo, S.R.; Zuo, X.C.; Wang, C.J.; Ma, Y.T.; Zhang, H.Y.; Li, Z.J.; Song, L.Y.; Deng, Z.Z.; Liu, S.K. A meta-analysis comparing the efficacy of entecavir and tenofovir for the treatment of chronic hepatitis B infection. J. Clin. Pharmacol. 2015, 55, 288–297
[22]	Wu, X.; Zhou, J.; Xie, W.; Ding, H.; Ou, X.; Chen, G.; Ma, A.; Xu, X.; Ma, H.; Xu, Y.; Liu, X.; Meng, T.; Wang, L.; Sun, Y.; Wang, B.; Kong, Y.; Ma, H.; You, H.; Jia, J. Entecavir monotherapy versus de novo combination of lamivudine and adefovir for compensated hepatitis B virus-related cirrhosis: a real-world prospective multicenter cohort study. Infect. Drug Resist. 2019, 12, 745–757.
[23]	Xu, K.R.; Liu, L.M.; Farazi, P.A.; Wang, H.M.; Rochling, F.A.; Watanabe-Galloway, S.; Zhang, J.J. Adherence and perceived barriers to oral antiviral therapy for chronic hepatitis B. Glob. Heal. Action. 2018, 11, 1433987.